Novo Nordisk's next-generation weight-loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it US$ 21.78 Min. order: 1 piece ★★★★★ 4.3 (53 reviews) Sold : Login>>
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management US$ 27.43 Min. order: 1 piece ★★★★★ 4.6 (171 reviews) Sold : Login>>
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.77 Min. order: 1 piece ★★★★★ 4.9 (106 reviews) Sold : Login>>
Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application US$ 28.54 Min. order: 1 piece ★★★★★ 4.4 (264 reviews) Sold : Login>>
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment US$ 29.70 Min. order: 1 piece ★★★★★ 4.8 (193 reviews) Sold : Login>>
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 28.13 Min. order: 1 piece ★★★★★ 4.4 (108 reviews) Sold : Login>>